Business
PAOG Announces CEO Interview Discussing Cannabis Investigational New Drug Application Plans With FDA
PAOG Announces CEO Interview Discussing Cannabis Investigational New Drug Application Plans With FDA.
About this update from Pao Group, Inc.
[{"type":"text","content":"\n\n\n\nPAOG Announces CEO Interview Discussing Cannabis Investigational New Drug Application Plans With FDA\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nPAOG Announces CEO Interview Discussing Cannabis Investigational New Drug Application Plans With FDA\nPR Newswire\nSANDUSKY, Ohio, Oct. 2, 2020\n\n\n\nSANDUSKY, Ohio, Oct. 2, 2020 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today announced an interview of CEO Jim DiPrima on MoneyTV where Mr. DiPrima discusses recent news regarding PAOG's latest moves to engage a contract research organization (CRO) to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA).\nMoneyTV is the internationally syndicated television program all about money and what makes it happen, (http://www.moneytv.net), featuring informative interviews with company CEOs and executives, providing insights into their operations and outlooks for their futures. MoneyTV is seen in over 200 million TV households in more than 75 countries.\nFree information packages from the featured companies can be requested by sending an email to [email protected].\nThe television program can also be viewed online immediately at www.moneytv.net.\nIn the interview released today Mr. DiPrima highlights the engagement of  Saul Kaye, the founder of iCAN (www.israel-cannabis.com) and CannaTech (www.canna-tech.co) to provide an independent review of PAOG's RespRx research for the treatment of Chronic Obstructive Pulmonary Disease (COPD), and to help prepare RexpRx for engaging with a contract research organization (CRO) to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA).\nSaul is a licensed pharmacist and a serial entrepreneur with both retail and e-commerce experience. He has founded multiple companies spanning six countries across the US, Europe, Israel and Australia.\nSaul Kaye is a global influencer in the medical cannabis industry, a widely respected speaker on cannabis industry movements and has been engaged in the past by other notable cannabis industry participants...